Canaccord raised the firm’s price target on Insulet to $234 from $226 and keeps a Buy rating on the shares. The firm said they are becoming more bullish given the significant T2 opportunity that they believe could provide a multi-year tailwind for the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD: